Peptomyc is a biotech startup that develops innovative cancer treatments. The company's primary focus is on creating a new generation of cell penetrating peptides (CPPs), which are small proteins that can penetrate cell membranes. These CPPs are designed to target a specific protein called Myc, which is often found in abnormal amounts in cancer cells. By targeting Myc, Peptomyc aims to create more effective cancer treatments.

The company was established in 2014, based on the research of Dr. Soucek, who has spent over two decades studying Omomyc, currently the most effective known inhibitor of the Myc protein. Peptomyc's approach is unique in the cancer treatment market, which currently relies on methods like surgery, radiotherapy, and chemotherapy. These traditional treatments often fail due to the development of resistance in cancer cells.

Peptomyc's business model revolves around the development and commercialization of their Myc-targeting CPPs. The company's potential market is vast, given the high global incidence of cancer, which exceeds 18 million cases per year and is expected to increase by 62% over the next two decades. Despite the crucial role of the Myc protein in cancer, there are currently no Myc inhibitors available in the market, presenting a significant opportunity for Peptomyc.

In terms of revenue, Peptomyc is likely to generate income through the sale of their innovative cancer treatments to healthcare providers once they have been fully developed and approved for use.

Keywords: Peptomyc, Biotech Startup, Cancer Treatment, Cell Penetrating Peptides, Myc Protein, Omomyc, Cancer Resistance, Myc Inhibitor, Healthcare Providers, Cancer Incidence.